Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation-Reference-Cited by-同舟云学术

Subcutaneous bortezomib in newly diagnosed patients with multiple myeloma nontransplant eligible: Retrospective evaluation

Published:2018-10 Issue:4 Volume:55 Page:189-196
ISSN:0037-1963
Container-title:Seminars in Hematology
language:en
Short-container-title:Seminars in Hematology

Author:

de Arriba de la Fuente Felipe,Durán Maria Soledad,Álvarez Miguel Ángel,Sanromán Isabel López,Dios Ana Maria,Ríos Tamayo Rafael,García Ricarda^ORCID,González Marta Sonia,Prieto Elena,Bárez Abelardo,Escalante Fernando,Tejedor Aurelia^ORCID,Ballesteros Mónica^ORCID,Cabañas Valentín^ORCID,Capote Francisco Javier,Couto Carmen,Garzón Sebastián,González-Pardo Miriam,Mateos Manteca Maria Victoria

Publisher

Elsevier BV

Subject

Hematology

Reference19 articles.

1. Front line treatment of elderly multiple myeloma in the era of novel agents;Venon;Biol Targets Ther,2009

2. Concise review—treatment of multiple myeloma in the very elderly: How do novel agents fit in?;Kint;J Geriatr Oncol,2016

3. Academy of Geriatric Cancer Research (AgeCare). Trends in hematological cancer in the elderly in Denmark, 1980-2012;Ocias;Acta Oncol Stockh Swed,2016

4. Initial treatment of transplant-ineligible patients in multiple myeloma;Mateos;Expert Rev Hematol,2014

5. VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma;San Miguel;N Engl J Med,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16;Blood Advances;2024-07-12

2. Real-world Outcomes in Newly Diagnosed Multiple Myeloma Based on Interphase Fluorescent In situ Hybridization: A Retrospective Analysis;Apollo Medicine;2024-04-04

3. Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant‐ineligible patients with myeloma who are treated with bortezomib‐based induction;European Journal of Haematology;2021-06-26

4. Dose intensity and treatment duration of bortezomib in transplant‐ineligible newly diagnosed multiple myeloma;European Journal of Haematology;2021-05-26

5. Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data;Frontiers in Pharmacology;2020-12-11